Filtered By:
Source: Journal of Drugs in Dermatology
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 900 results found since Jan 2013.
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.PMID:37276166 | DOI:10.36849/JDD.7432
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Danny Zakria Nicholas Brownstone April W Armstrong Erin E Boh John Y M Koo Joseph F Merola David Pariser Mark Lebwohl Source Type: research
Neurogenic Rosacea Treatment: A Literature Review
J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181.ABSTRACTRosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patie...
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Mirjana G Ivanic Aislyn Oulee Alexandra Norden Sogol S Javadi Michael H Gold Jashin J Wu Source Type: research
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.PMID:37276166 | DOI:10.36849/JDD.7432
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Danny Zakria Nicholas Brownstone April W Armstrong Erin E Boh John Y M Koo Joseph F Merola David Pariser Mark Lebwohl Source Type: research
Neurogenic Rosacea Treatment: A Literature Review
J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181.ABSTRACTRosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patie...
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Mirjana G Ivanic Aislyn Oulee Alexandra Norden Sogol S Javadi Michael H Gold Jashin J Wu Source Type: research
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.PMID:37276166 | DOI:10.36849/JDD.7432
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Danny Zakria Nicholas Brownstone April W Armstrong Erin E Boh John Y M Koo Joseph F Merola David Pariser Mark Lebwohl Source Type: research
Neurogenic Rosacea Treatment: A Literature Review
J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181.ABSTRACTRosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patie...
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Mirjana G Ivanic Aislyn Oulee Alexandra Norden Sogol S Javadi Michael H Gold Jashin J Wu Source Type: research
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.PMID:37276166 | DOI:10.36849/JDD.7432
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Danny Zakria Nicholas Brownstone April W Armstrong Erin E Boh John Y M Koo Joseph F Merola David Pariser Mark Lebwohl Source Type: research
Neurogenic Rosacea Treatment: A Literature Review
J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181.ABSTRACTRosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patie...
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Mirjana G Ivanic Aislyn Oulee Alexandra Norden Sogol S Javadi Michael H Gold Jashin J Wu Source Type: research
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus Panel
CONCLUSION: Choosing a biologic medication for psoriasis often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing precision medicine tests such as Mind.Px can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal medication through a targeted and evidence-based approach. Zakria D, Brownstone N, Armstrong AW, et al. Integrating precision medicine into medical dermatology clinical practice: an expert consensus panel. J Drugs Dermatol. 2023;22(6):588-593. doi:10.36849/JDD.7432.PMID:37276166 | DOI:10.36849/JDD.7432
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Danny Zakria Nicholas Brownstone April W Armstrong Erin E Boh John Y M Koo Joseph F Merola David Pariser Mark Lebwohl Source Type: research
Neurogenic Rosacea Treatment: A Literature Review
J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181.ABSTRACTRosacea is a chronic skin disorder involving central facial erythema secondary to vascular instability and cutaneous inflammation. Rosacea is divided into different subtypes based on the morphology of the rash — erythematotelangiectatic, papulopustular, phymatous, and ocular rosacea. A less-known subtype called neurogenic rosacea has been proposed to categorize patients suffering from rosacea with erythematous flushing and burning sensation that is refractory to traditional treatment. There is minimal data on this subgroup of rosacea patie...
Source: Journal of Drugs in Dermatology - June 5, 2023 Category: Dermatology Authors: Mirjana G Ivanic Aislyn Oulee Alexandra Norden Sogol S Javadi Michael H Gold Jashin J Wu Source Type: research
A Review of Antithrombotic Agents in Dermatologic Surgery and Context for a Practical Approach, With Cardiology and Pharmacologic Input
J Drugs Dermatol. 2023 May 1;22(5):496-501. doi: 10.36849/JDD.7456.ABSTRACTDermatologic surgeons are encountering more patients on antithrombotic agents. There are no established consensus guidelines for managing antithrombotic agents in the perioperative period. We provide an updated overview of antithrombotic agents in dermatologic surgery and management of such agents in the perioperative period with additional unique perspectives from cardiology and pharmacy. A literature search of PubMed and Google Scholar was performed to review the English-language medical literature. The landscape of antithrombotic therapy is chang...
Source: Journal of Drugs in Dermatology - May 3, 2023 Category: Dermatology Authors: Elizabeth Rao Wyatt Andrasik Basia Michalski Khaldoun Tarakji Michael Militello Jennifer Lucas Source Type: research
Allergens in Common Brands of Clobetasol
CONCLUSIONS: Forty-nine different ingredients were identified among all 18 products included, with an average of 8.4 ingredients per product; 19 of these ingredients have allergenic potential, while one has protective effects. Two branded foam formulations contained the greatest number of potential allergens (5), while a shampoo formulation contained no potential allergens. Knowing which allergens are present in different products may be helpful when treating a patient with an allergy or suspected allergy to one of these ingredients. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.4651.PMID:37133477 | DOI:10.36849/JDD.4651
Source: Journal of Drugs in Dermatology - May 3, 2023 Category: Dermatology Authors: Leena Ramani Wasim Haidari Shalanda Hall Sima Amin Sarah Chisolm Steven Feldman Source Type: research
